Viewing nowCombinationSildapamil Extended Release Tablets 5/50/750 mg
Sitagliptin Phosphate Hydrate 64.3mg · Dapagliflozin Propanediol Hydrate 6.2mg +1 more
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 202301625 · Approved 2023.05.22 · Insurance code 643508700
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist in blood glucose control for patients with type 2 diabetes. It is particularly effective when used in combination with dapagliflozin, sitagliptin, and metformin, and better results can be expected when combined with dietary and exercise therapy. This medication helps to manage blood glucose levels stably, aiding in the treatment of diabetes.
The recommended dose of this medicine for antidiabetic therapy is 10mg of dapagliflozin and 100mg of sitagliptin; the dose of extended-release metformin hydrochloride should be determined based on each patient's current treatment regimen, efficacy, and tolerability, and should not exceed 2000mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine with food once daily, preferably in the evening. If the dose of metformin hydrochloride needs adjustment, adjust it gradually. Patients taking this medicine as the 5/50/500mg, 5/50/750mg, or 5/50/1000mg extended-release tablet should take 2 tablets once daily. Patients who do not achieve adequate glycemic control with combination therapy of metformin hydrochloride and sitagliptin should start this medicine at dapagliflozin 10mg, sitagliptin 100mg, and the current dose of metformin hydrochloride or a therapeutically similar dose. For patients switching to this medicine from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride, the dose of this medicine should correspond to the previous doses of each component. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Since changes may cause changes in glycemic control, any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. This medicine may not dissolve completely and may be excreted in the stool. It is unknown whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General Precautions). Special populations Patients with renal impairment The efficacy and safety of this medicine depend on renal function, and dosage adjustment according to renal function is required. Therefore, renal function should be assessed before and periodically after administration of this medicine. No dosage adjustment is necessary in patients with mild renal impairment. In patients with eGFR of 45mL/min/1.73m2 or higher and below 60mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If eGFR falls below 45mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
This medication contains sitagliptin, dapagliflozin, and metformin, which are used for the treatment of diabetes. First, the sitagliptin component can rarely cause serious allergic reactions, so if sudden rashes, difficulty breathing, or swelling of the face or neck occur after taking the medication, discontinue use immediately and seek medical care. Additionally, acute pancreatitis, which is inflammation of the pancreas, can occur, so if symptoms like abdominal pain, vomiting, or nausea arise, it is important to visit a hospital promptly. Next, the dapagliflozin component can reduce body fluid volume, potentially lowering blood pressure, thus caution is necessary for patients at risk of dehydration or hypotension. There is an increased risk of genital and urinary tract infections, so prompt treatment is necessary if any symptoms of infection are present. Also, very rarely, serious perineal necrosis, which is damage to skin and tissues, may occur; therefore, if pain, swelling, or redness appears around the genital area, consult medical personnel immediately. The metformin component can very rarely cause lactic acidosis, a serious metabolic disturbance; thus, if symptoms such as severe fatigue, difficulty breathing, or abdominal pain arise, immediate treatment is necessary. Patients with poor liver function or decreased kidney function should limit the use of this medication and undergo regular kidney and liver function tests. Additionally, there is a risk of hypoglycemia, so blood glucose changes should be monitored carefully if meals are skipped or irregular, if vigorous exercise is performed, or if insulin or other diabetes medications are used concurrently. This medication should not be administered to patients who are pregnant or have severe infections, heart failure, or acute myocardial infarction. While taking this medication, it is important to closely observe any changes in health status and to consult a doctor immediately if abnormal symptoms occur.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. The optimal storage temperature is between 1 degree and 30 degrees Celsius at room temperature. Proper storage will help maintain the efficacy of the medication for a longer duration and ensure safe usage.
Pale yellow oval-shaped extended release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Phosphate Hydrate 64.3mg · Dapagliflozin Propanediol Hydrate 6.2mg +1 more
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.3mg · Dapagliflozin Propanediol Hydrate 6.2mg +1 more
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.3mg · Dapagliflozin Propanediol Hydrate 6.2mg +1 more
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg +1 more
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg +1 more
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg +1 more
Tablet · Prescription medication · Combination
Dongkuk Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg +1 more
Tablet · Prescription medication · Combination
Dongkook Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg +1 more
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.